Physician profile
William Charles Myers
NPI 1457316861
$4,146.63
in general payments reported to CMS, 2019-2025
23 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 90% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.23 · 2020: $134 · 2021: $1,383 · 2022: $358 · 2023: $442 · 2024: $383 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,219 · Travel and Lodging: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.56 |
| Travel and Lodging | $1,030.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $1,374.06 | 2024-2025 | |
| Peerless Surgical INC. | $1,231.03 | 2021 | |
| Medtronic, INC. | $258.05 | 2022-2024 | Intellis Adaptivestim |
| Linvatec Corporation | $236.98 | 2023-2024 | 5ms |
| Imbed Biosciences INC. | $207.13 | 2023 | |
| Kerecis Limited | $145.81 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Horizon Therapeutics Plc | $141.01 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $116.57 | 2023-2025 | Nuzyra |
| Grt US Holding, INC. | $94.79 | 2022 | |
| Misonix INC | $53.58 | 2021 | |
| Smith+Nephew, INC. | $38.48 | 2024 | Grafix Pl, Stravix |
| Terumo Bct, INC. | $37.43 | 2021 | |
| Heron Therapeutics, INC. | $35.53 | 2021-2022 | |
| Paragon 28, INC. | $24.96 | 2024 | Mtp |
| Merck Sharp & Dohme LLC | $22.23 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acumed LLC | $20.18 | 2025 | Acumed |
| Melinta Therapeutics, LLC | $18.43 | 2021 | |
| Polynovo North America LLC | $16.88 | 2023 | |
| Next Science LLC | $15.89 | 2023 | Blastx, Surgx, Xperience |
| Ani Pharmaceuticals, INC. | $15.82 | 2025 | Purified Cortrophin Gel |
| Triad Life Sciences INC. | $15.81 | 2022 | |
| Nevro Corp. | $14.71 | 2024 | Senza |
| Medela LLC | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.